Dihydropyrimidine Dehydrogenase Deficiency
What's New
Last Posted: Mar 07, 2023
- Cost Implications of Reactive Versus Prospective Testing for Dihydropyrimidine Dehydrogenase Deficiency in Patients With Colorectal Cancer: A Single-Institution Experience.
Murphy Con, et al. Dose-response : a publication of International Hormesis Society 2018 0 (4) 1559325818803042 - Three different polymorphisms of the DPYD gene associated with severe toxicity following administration of 5-FU: a case report.
Mukherji Deborah, et al. Journal of medical case reports 2019 0 (1) 76 - A comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency.
Pallet Nicolas, et al. British journal of cancer 2020 0 (5) 811-818 - DPYD Exome, mRNA Expression and Uracil Levels in Early Severe Toxicity to Fluoropyrimidines: An Extreme Phenotype Approach.
Villalvazo Priscila, et al. Journal of personalized medicine 2021 0 (8) - Predicting Dihydropyrimidine Dehydrogenase Deficiency and Related 5-Fluorouracil Toxicity: Opportunities and Challenges of DPYD Exon Sequencing and the Role of Phenotyping Assays.
De Luca Ottavia, et al. International journal of molecular sciences 2022 0 (22) - Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency.
van Kuilenburg André B P, et al. Annals of clinical biochemistry 2003 0 (Pt 1) 41-5 - Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency.
Etienne-Grimaldi Marie-Christine et al. European journal of cancer (Oxford, England : 1990) 2023 1813-17 - Testing for Dihydropyrimidine Dehydrogenase Deficiency to Individualize 5-Fluorouracil Therapy.
Diasio Robert B et al. Cancers 2022 14(13) - Dihydropyrimidine Dehydrogenase Deficiency and Implementation of Upfront DPYD Genotyping.
White Cassandra et al. Clinical pharmacology and therapeutics 2022 - [Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists].
Loriot Marie-Anne et al. Bulletin du cancer 2019 106(9) 759-775
More
About Rare Diseases PHGKB
Rare Disease PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other information that address the public health impact and translation of genomic and other precision health discoveries into improved health outcomes related to rare diseases...more
Content Summary
Selected Rare Diseases
- Alpha-1 Antitrypsin Deficiency
- Amyotrophic Lateral Sclerosis
- Brugada Syndrome
- Cerebral Palsy
- Cystic Fibrosis
- Duchenne Muscular Dystrophy
- Eclampsia
- Erythema Multiforme
- Familial Mediterranean Fever
- Fragile X Syndrome
- Gaucher Disease
- Glomerulonephritis
- Graves Disease
- Hemophilia
- Huntington Disease
- Microcephaly
- Myasthenia Gravis
- Phenylketonuria
- Retinitis Pigmentosa
- Severe Combined Immunodeficiency
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by Public Health Genomics Branch to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
- Page last reviewed:Feb 1, 2024
- Page last updated:May 18, 2024
- Content source: